Liệu pháp quang động lực học sớm so với muộn cho bệnh lý chorioretinopathy trung tâm serous mãn tính

You EL, Hébert M, Jin TS, Bourgault S, Caissie M, Tourville É, Chen J, Ordóñez-Mena J, Dirani A (2023) Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis. Surv Ophthalmol. https://doi.org/10.1016/j.survophthal.2023.03.001 van Dijk EHC, Feenstra HMA, Bjerager J, Grauslund J, Boon CJF, Subhi Y (2023) Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses. Acta Ophthalmol 101(2):140–159. https://doi.org/10.1111/aos.15263 Goté JT, Singh SR, Chhablani J (2023) Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-023-05996-4 Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, Pires IA, Cunha-Vaz JG, Murta JN (2013) Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina 33(2):309–315. https://doi.org/10.1097/IAE.0b013e3182670fbe Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S (2013) Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 33(2):316–323. https://doi.org/10.1097/IAE.0b013e318280769c Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28(8):944–957. https://doi.org/10.1038/eye.2014.134 Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122(3):555–561. https://doi.org/10.1016/j.ophtha.2014.09.034 Sheptulin V, Purtskhvanidze K, Roider J (2018) Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 256(11):2027–2034. https://doi.org/10.1007/s00417-018-4086-6 Nicolò M, Desideri LF, Vagge A, Traverso CE (2020) Current pharmacological treatment options for central serous chorioretinopathy: a review. Pharmaceuticals (Basel) 13(10):264. https://doi.org/10.3390/ph13100264.PMID:32977380;PMCID:PMC7597965 Hashizume K, Mizota A, Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF (2014) Macula society CSC collaborative study group, research and education committee and website committee. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121(5):1073–1078. https://doi.org/10.1016/j.ophtha.2013.11.040 Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, CardilloPiccolino F (2014) Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 157(5):1033–1037. https://doi.org/10.1016/j.ajo.2014.01.022 Alkin Z, Perente I, Ozkaya A, Alp D, Agca A, Aygit ED, Korkmaz S, Yazici AT, Demirok A (2014) Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Clin Ophthalmol 5(8):685–690. https://doi.org/10.2147/OPTH.S58617 Kim YK, Ryoo NK, Woo SJ, Park KH (2015) Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 253(12):2063–2073. https://doi.org/10.1007/s00417-014-2926-6 Shiode Y, Morizane Y, Kimura S, Hosokawa M, Kawata T, Doi S, Hosogi M, Fujiwara A, Shiraga F (2015) Comparison of halving the irradiation time or the verteporfin dose for chronic central serous chorioretinopathy. Retina 35(12):2498–2504. https://doi.org/10.1097/IAE.0000000000000621 Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT (2016) Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 167:57–64. https://doi.org/10.1016/j.ajo.2016.04.001 Cheng CK, Chang CK, Peng CH (2017) Comparison of photodynamic therapy using half dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37(2):325–333. https://doi.org/10.1097/IAE.0000000000001138 Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLoS ONE 12(7):e0181479. https://doi.org/10.1371/journal.pone.0181479 Matušková V, Vysloužilová D, Uher M (2018) Half-Fluence photodynamic therapy for chronic central serous chorioretinopathy: predisposing factors for visual acuity outcomes. Semin Ophthalmol 33(5):690–699. https://doi.org/10.1080/08820538.2017 Chung CY, Chan YY, Li KKW (2018) Angiographic and tomographic prognostic factors of chronic central serous chorioretinopathy treated with half-dose photodynamic therapy. Ophthalmologica 240(1):37–44. https://doi.org/10.1159/000484100 van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF (2018) Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 256(8):1395–1402. https://doi.org/10.1007/s00417-018-4003-z. (Epub 2018 May 7) Asano KS, Asaoka R, Asano S, Azuma K, Inoue T, Obata R (2020) Elongated photoreceptor outer segment length and prognosis of chronic central serous chorioretinopathy. Retina 40(4):750–757. https://doi.org/10.1097/IAE.0000000000002445 van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125(10):1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021 van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003 Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, on behalf of the VICI trial investigators et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395(10220):294–303. https://doi.org/10.1016/S0140-6736(19)32981-2 Missotten TO, Hoddenbach JG, Eenhorst AE, van den Born LI, Martinez Ciriano JP, Wubbels RJ (2021) A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakage. Eur J Ophthalmol. 31(3):1248–1253. https://doi.org/10.1177/1120672120915168 Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central Serous Chorioretinopathy: a Review of Epidemiology and Pathophysiology. Clin Exp Ophthalmol 41(2):201–214. https://doi.org/10.1111/j.1442-9071.2012.02848.x Zhang X, Zhuang X, Dong J, Fu B, Xu L (2022) Factors for recurrence in acute central serous chorioretinopathy patients underwent one-third dose verteporfin photodynamic therapy. Photodiagnosis Photodyn Ther. 39:102984. https://doi.org/10.1016/j.pdpdt.2022.102984 Mrejen S, Balaratnasingam C, Kaden TR et al (2019) Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 126(4):576–588. https://doi.org/10.1016/j.ophtha.2018.12.048 Reibaldi M, Boscia F, Avitabile T, Russo A, Cannemi V, Uva MG, Reibaldi A (2009) Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy. Eur J Ophthalmol 19(1):154–158 Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F (2009) A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 73(3):435–437 Arora S, Maltsev DS, Sahoo NK, Parameshwarappa DC, Iovino C, Arora T et al (2022) Visual acuity correlates with multimodal imaging-based categories of central serous chorioretinopathy. Eye (Lond) 36(3):517–523. https://doi.org/10.1038/s41433-021-01788-4 Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M (2019) Chronic central serous chorioretinopathy: early and late morphological and functional changes after verteporfin photodynamic therapy. Retina 39(5):980–987. https://doi.org/10.1097/IAE.0000000000002040 Kumashiro S, Takagi S, Itokawa T, Tajima A, Kobayashi T, Hori Y (2021) Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. BMC Ophthalmol. 21(1):241. https://doi.org/10.1186/s12886-021-01980-w Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555 Feenstra HMA, Diederen RMH, Lamme MJCM, Tsonaka R, Fauser S, Yzer S et al (2023) Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy. Retina 43(3):379–388. https://doi.org/10.1097/IAE.0000000000003686. (Epub 2023 Jan 2) Altinel MG, Kanra AY, GedarTotuk OM, Ardagil A, Kabadayi K (2021) Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 33:102081. https://doi.org/10.1016/j.pdpdt.2020.102081